Patents by Inventor J. Vaughan
J. Vaughan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20120258114Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF? and for inhibiting hTNF? activity, e.g., in a human subject suffering from a disorder in which hTNF? activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.Type: ApplicationFiled: June 15, 2012Publication date: October 11, 2012Inventors: JOCHEN G. SALFELD, DEBORAH J. ALLEN, HENDRICUS R.J.M. HOOGENBOOM, ZEHRA KAYMACALAN, BORIS LABKOVSKY, JOHN A. MANKOVICH, BRIAN T. MCGUINNESS, ANDREW J. ROBERTS, PAUL SAKORAFAS, DAVID SCHOENHAUT, TRISTAN J. VAUGHAN, MICHAEL WHITE, ALISON J. WILTON
-
Publication number: 20120219564Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF? and for inhibiting hTNF? activity, e.g., in a human subject suffering from a disorder in which hTNF? activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.Type: ApplicationFiled: May 8, 2012Publication date: August 30, 2012Applicant: ABBOTT BIOTECHNOLOGY LTD.Inventors: JOCHEN G. SALFELD, DEBORAH J. ALLEN, HENDRICUS R.J.M. HOOGENBOOM, ZEHRA KAYMAKCALAN, BORIS LABKOVSKY, JOHN A. MANKOVICH, BRIAN T. MCGUINNESS, ANDREW J. ROBERTS, PAUL SAKORAFAS, DAVID SCHOENHAUT, TRISTAN J. VAUGHAN, MICHAEL WHITE, ALISON J. WILTON
-
Publication number: 20120178107Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF? and for inhibiting hTNF? activity, e.g., in a human subject suffering from a disorder in which hTNF? activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.Type: ApplicationFiled: December 30, 2011Publication date: July 12, 2012Applicant: Abbott Biotechnology Ltd.Inventors: Jochen G. Salfeld, Deborah J. Allen, Hendricus R.J.M. Hoogenboom, Zehra Kaymakcalan, Boris Labkovsky, John A. Mankovich, Brian T. McGuinness, Andrew J. Roberts, Paul Sakorafas, David Schoenhaut, Tristan J. Vaughan, Michael White, Alison J. Wilton
-
Patent number: 8206714Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF? and for inhibiting hTNF? activity, e.g., in a human subject suffering from a disorder in which hTNF? activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.Type: GrantFiled: February 11, 2009Date of Patent: June 26, 2012Assignee: Abbott Biotechnology Ltd.Inventors: Jochen G. Salfeld, Deborah J. Allen, Zehra Kaymakcalan, Boris Labkovsky, John A. Mankovich, Brian T. McGuinness, Andrew J. Roberts, Paul Sakorafas, Hendricus R. J. M. Hoogenboom, David Schoenhaut, Tristan J. Vaughan, Michael White, Alison J. Wilton
-
Patent number: 8197813Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF? and for inhibiting hTNF? activity, e.g., in a human subject suffering from a disorder in which hTNF? activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.Type: GrantFiled: March 10, 2009Date of Patent: June 12, 2012Assignee: Abbott Biotechnology Ltd.Inventors: Jochen G. Salfeld, Deborah J. Allen, Hendricus R. J. M. Hoogenboom, Zehra Kaymakcalan, Boris Labkovsky, John A. Mankovich, Brian T. McGuinness, Andrew J. Roberts, Paul Sakorafas, David Schoenhaut, Tristan J. Vaughan, Michael White, Alison J. Wilton
-
Publication number: 20100040604Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF? and for inhibiting hTNF? activity, e.g., in a human subject suffering from a disorder in which hTNF? activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.Type: ApplicationFiled: October 13, 2009Publication date: February 18, 2010Inventors: Jochen G. SALFELD, Deborah J. Allen, Hendricus R.J.M. Hoogenboom, Zehra Kaymakcalan, Boris Labkovsky, John A. Mankovich, Brian T. McGuinness, Andrew J. Roberts, Paul Sakorafas, David Schoenhaut, Tristan J. Vaughan, Michael White, Alison J. Wilton
-
Publication number: 20100016557Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF? and for inhibiting hTNF? activity, e.g., in a human subject suffering from a disorder in which hTNF? activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.Type: ApplicationFiled: March 10, 2009Publication date: January 21, 2010Applicant: Abbott Biotechnology Ltd.Inventors: Jochen G. Salfeld, Deborah J. Allen, Hendricus R.J.M. Hoogenboom, Zehra Kaymakcalan, Boris Labkovsky, John A. Mankovich, Brian T. McGuinness, Andrew J. Roberts, Paul Sakorafas, David Schoenhaut, Tristan J. Vaughan, Michael White, Alison J. Wilton
-
Patent number: 7588761Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF? and for inhibiting hTNF? activity, e.g., in a human subject suffering from a disorder in which hTNF? activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.Type: GrantFiled: September 21, 2005Date of Patent: September 15, 2009Assignee: Abbott Biotechnology Ltd.Inventors: Jochen G. Salfeld, Deborah J. Allen, Hendricus R. J. M. Hoogenboom, Zehra Kaymakcalan, Boris Labkovsky, John A. Mankovich, Brian T. McGuinness, Andrew J. Roberts, Paul Sakorafas, David Schoenhaut, Tristan J. Vaughan, Michael White, Alison J. Wilton
-
Publication number: 20090155205Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF? and for inhibiting hTNF? activity, e.g., in a human subject suffering from a disorder in which hTNF? activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.Type: ApplicationFiled: February 11, 2009Publication date: June 18, 2009Inventors: Jochen G. Salfeld, Deborah J. Allen, Hendricus R.J.M Hoogenboom, Zehra Kaymakcalan, Boris Labkovsky, John A. Mankovich, Brian T. McGuinness, Andrew J. Roberts, Paul Sakorafas, David Schoenhaut, Tristan J. Vaughan, Michael White, Alison J. Wilton
-
Patent number: 7541031Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF? and for inhibiting hTNF? activity, e.g., in a human subject suffering from a disorder in which hTNF? activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.Type: GrantFiled: April 17, 2007Date of Patent: June 2, 2009Assignee: Abbott Biotechnology Ltd.Inventors: Jochen G. Salfeld, Deborah J. Allen, Zehra Kaymakcalan, Boris Labkovsky, John A. Mankovich, Brian T. McGuinness, Andrew J. Roberts, Paul Sakorafas, Hendricus R. J. M. Hoogenboom, David Schoenhaut, Tristan J. Vaughan, Michael White, Alison J. Wilton
-
Publication number: 20080129298Abstract: This document discloses, among other things, multi-channel magnetic resonance using a TEM coil.Type: ApplicationFiled: February 17, 2007Publication date: June 5, 2008Inventors: J. Vaughan, Pierre-Francois Moortele, Lance DelaBarre, Christopher Olson, Heather Orser, Anand Gopinath, Kamil Ugurbil, Carl Snyder, Gregor Adriany, Can Akgun, Jinfeng Tian, John Strupp, Peter Andersen, Xiaoping Wu
-
Publication number: 20080088305Abstract: Technology for controlling non-uniformity in the B1 field includes selecting the phase, magnitude, frequency, time, or spatial relationship among various elements of a multi-channel excitation coil in order to control the radio frequency (RF) power emanating from the coil antenna elements. Non-uniformity can be used to steer a constructively interfering B1 field node to spatially correlate with an anatomic region of interest. A convex (quadratically constrained quadratic problem) formulation of the B1 localization problem can be used to select parameters for exciting the coil. Localization can be used in simulated Finite Difference Time Domain B1 field human head distributions and human head phantom measurement.Type: ApplicationFiled: May 3, 2007Publication date: April 17, 2008Inventors: Christopher Olson, J. Vaughan, Anand Gopinath
-
Publication number: 20080084210Abstract: A current unit having two or more current paths allows control of magnitude, phase, time, frequency and position of each of element in a radio frequency coil. For each current element, the current can be adjusted as to a phase angle, frequency and magnitude. Multiple current paths of a current unit can be used for targeting multiple spatial domains or strategic combinations of the fields generated/detected by combination of elements for targeting a single domain in magnitude, phase, time, space and frequency.Type: ApplicationFiled: September 20, 2007Publication date: April 10, 2008Applicant: REGENTS OF THE UNIVERSITY OF MINNESOTAInventors: J. Vaughan, Gregor Adriany, Carl Snyder, Can Akgun, Jinfeng Tian, Kamil Ugurbil, Pierre-Francois Van de Moortele, Steen Moeller
-
Publication number: 20070290688Abstract: An RF coil suitable for use in imaging systems is provided which coil has a dielectric filled cavity formed by a surrounding conducting enclosure, the conducting enclosure preferably being patterned to form continuous electrical paths around the cavity, each of which paths may be tuned to a selected resonant frequency. The patterning breaks up any currents induced in the coil and shortens path lengths to permit higher frequency, and thus higher field strength operation. The invention also includes improved mechanisms for tuning the resonant frequency of the paths, for selectively detuning the paths, for applying signal to the coil, for shortening the length of the coil and for controlling the field profile of the coil and the delivery of field to the object to the image.Type: ApplicationFiled: August 31, 2007Publication date: December 20, 2007Applicant: THE GENERAL HOSPITAL CORPORATIONInventor: J. Vaughan
-
Publication number: 20070289028Abstract: A computer readable media containing instructions for a processor to implement a plurality of steps comprising: accessing a time constraint for an entitlement, determining whether the time constraint has been satisfied, and responsive to the determination that the time constraint has been satisfied, modifying the entitlement, wherein the duration of the entitlement is less than the duration of the license for the digital content.Type: ApplicationFiled: June 27, 2006Publication date: December 13, 2007Applicant: Software Spectrum, Inc.Inventors: Michael J. Vaughan, Erich K. Jacobs, Craig S. Brusseau, Norman J. Dumont, Bruce C. Penney, John M. Covino
-
Publication number: 20070288389Abstract: Embodiments relate generally to ensuring version compliance for software products used within an enterprise. Generally, compliance is checked by comparing the number of actual uses of each product version to license information relating to product versions. An enterprise is compliant if use of a product version is covered by a license. License information and actual usage information are generally collected to allow for such a comparison. Information concerning license attributes such as downgrade coverage and/or license type may allow for a more accurate determination of the number of each product version ultimately available. Additionally, a rollup procedure may be used to apply updates to base licenses. Version compliance may be performed as a stand-alone feature, or it may be used in conjunction with an entitlement coordination framework to manage usage throughout the enterprise.Type: ApplicationFiled: December 29, 2006Publication date: December 13, 2007Inventors: Michael J. Vaughan, Erich K. Jacobs, Craig S. Brusseau, Norman J. Dumont, Bruce D. Penney, John M. Covino
-
Publication number: 20070247160Abstract: An RF coil suitable for use in imaging systems is provided which coil has a dielectric filled cavity formed by a surrounding conducting enclosure, the conducting enclosure preferably being patterned to form continuous electrical paths around the cavity, each of which paths may be tuned to a selected resonant frequency. The patterning breaks up any currents inducted in the coil and shortens path lengths to permit higher frequency, and thus higher field strength operation. The invention also includes improved mechanisms for tuning the resonant frequency of the paths, for selectively detuning the paths, for applying signal to the coil, for shortening the length of the coil and for controlling the field profile of the coil and the delivery of field to the object to the image.Type: ApplicationFiled: July 3, 2007Publication date: October 25, 2007Applicant: The General Hospital Corporation d/b/a Massachusetts General HospitalInventor: J. Vaughan
-
Patent number: 7223394Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor a (hTNF?) are disclosed. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF? and for inhibiting hTNF? activity, e.g., in a human subject suffering from a disorder in which hTNF? activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.Type: GrantFiled: March 7, 2001Date of Patent: May 29, 2007Assignee: Abbott Biotechnology LtdInventors: Jochen G. Salfeld, Deborah J. Allen, Hendricus R. J. M. Hoogenboom, Zehra Kaymakcalan, Boris Labkovsky, John A. Mankovich, Brian T. McGuinness, Andrew J. Roberts, Paul Sakorafas, David Schoenhaut, Tristan J. Vaughan, Michael White, Alison J. Wilton
-
Publication number: 20070108980Abstract: This document discusses, among other things, a system and method for a coil having a plurality of resonant elements and an adjustable frame. A position of at least one resonant element can be adjusted relative to at least one other resonant element. A variable impedance is coupled to adjacent resonant elements and the impedance varies as a function of a separation distance. Cables are coupled to each resonant element and are gathered at a junction in a particular manner.Type: ApplicationFiled: November 14, 2006Publication date: May 17, 2007Inventors: Gregor Adriany, Pierre-Francois Van de Moortele, Johannes Ritter, William Voje, J. Vaughan, Kamil Ugurbil
-
Publication number: 20070007964Abstract: An RF coil suitable for use in imaging systems is provided which coil has a dielectric filled cavity formed by a surrounding conducting enclosure, the conducting enclosure preferably being patterned to form continuous electrical paths around the cavity, each of which paths may be tuned to a selected resonant frequency. The patterning breaks up any currents inducted in the coil and shortens path lengths to permit higher frequency, and thus higher field strength operation. The invention also includes improved mechanisms for tuning the resonant frequency of the paths, for selectively detuning the paths, for applying signal to the coil, for shortening the length of the coil and for controlling the field profile of the coil and the delivery of field to the object to the image.Type: ApplicationFiled: September 15, 2006Publication date: January 11, 2007Inventor: J. Vaughan